

Innovative therapy, monoclonal antibodies and beyond - 6th Edition

Friday, 22 January 2016

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

PRESENTATION

Bio-immunotherapy of cancer is providing compelling proofs of clinical success in the comprehensive treatment of human malignancies. The increasing knowledge of the molecular mechanisms responsible for neoplastic transformation, the biology of cancer cells, and the immunological mechanisms regulating tumor-host interaction, allowed us to identify and apply more effective anti-cancer biological and immunological treatments. To date, the immuno-biotherapy is a continuously evolving treatment modality and it is currently integrated into the treatment algorithms of several different tumors. Furthermore, elucidating resistance mechanisms and exploiting cancer vulnerabilities to therapeutics will ultimately improve cancer therapy and patient care. For these reasons, a multidisciplinary approach, including clinical and pre-clinical professionals, is required. This conference explores topics that will appeal to clinicians, as well as, basic, translational, and clinical scientists ranging from academics to industry. As in the past, the meeting will provide a highly interactive forum in which leading experts will discuss clinical and pre-clinical data, providing the audience with a broad overview of the most recent achievements in cancer biologic and immunologic therapy.

PROGRAM

Welcome Coffee

- 08.00-09.00 Registration
09.00-09.10 Welcome remarks of Authorities
09.10 Introduction • M. Di Nicola (Milan)

I SESSION: Preclinical assays and novel biotargets

Chairmen: M. Del Vecchio (Milan); M.P. Colombo (Milan)

- 09.20-09.50 Mechanisms of immune evasion to check-point inhibitors • V. Russo (Milan)
09.50-10.20 Immunoscore: a prognostic and predictive tool • J. Galon (Paris)
10.20-10.50 TBD
10.50-11.20 Overriding the inflammatory microenvironment. • C. Tripodo (Palermo)
11.20-11.50 CD8+ TREG population: role in tumor microenvironment • A. Anichini, (Milan)
11.50-12.10 General discussion

Keynote Lecture

- 12.10-12.55 Tumor cell metabolism • G Kroemer (Paris)
Introduction: M.P. Colombo (Milan)

- 12.55-14.25 Buffet Lunch

NADIREX INTERNATIONAL Srl

II SESSION: Monoclonal antibodies, cell therapies and TK inhibitors

Chairmen: F. De Braud (Milan), M. Di Nicola (Milan)

- 14.25-14.55 Hooking TRAIL-R2 to “educate” immune system to recognize cancer cells • TBD
- 14.55-15.25 TVEC vaccination: rationale and immunological background • P. Queirolo (Genoa)
- 15.55-16.25 Overcoming resistance to targeted therapy • M. Del Vecchio (Milan)
- 16.25-16.55 Combined CTLA4 and PD-1 pathway blockade for treatment of advanced cancer •
M. Maio (Siena)
- 16.55-17.20 Discussion
- 17.20 Conclusions • M. Del Vecchio (Milan)